Asundexian reduced ischemic stroke risk by 26% after recent non-cardioembolic stroke or high-risk transient ischemic attack
FDA approved asundexian with antiplatelet therapy after recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack following a trial showing ...
